GLP-1s May Help Reduce Endometrial Cancer Risk in Patients With Obesity and Metabolic Disease

In this interview with Pharmacy Times, Jennifer MacDonald, PharmD, BCOP, MUSC Oncology PGY2 Residency Program Director, Clinical Oncology Pharmacy Specialist at Hollings Cancer Center, discusses the growing evidence linking GLP-1 receptor agonists to a reduced risk of endometrial cancer in patients with obesity and metabolic disease. MacDonald explains how rising rates of endometrial cancer, particularly aggressive forms disproportionately affecting African American women, highlight the importance of preventive strategies targeting obesity and metabolic syndrome. She also discusses the evolving role of pharmacists in identifying high-risk patients and educating providers about integrating GLP-1 therapies alongside traditional progestin-based approaches for conditions such as endometriosis, PCOS, atypical hyperplasia, and fertility-preserving treatment strategies.